Epsilon Healthcare Limited (AU:EPN)
ASX:EPN
Top Page
Epsilon Healthcare Limited
(Sydney:EPN)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.02
▲(5.00% Upside)
Action:ReiteratedDate:03/24/26
The score is weighed down primarily by weak financial performance: persistent losses, consistently negative cash flow, and a sharp rise in leverage in 2025 despite the revenue rebound. Technicals also remain soft with price below key moving averages and negative MACD. Valuation offers limited support because the company is unprofitable (negative P/E) and has no stated dividend yield.
Positive Factors
Manufacturing Capabilities
Owning cGMP-compliant extraction and manufacturing facilities is a durable competitive asset: it supports regulatory approvals, consistent product quality, and enables contract/private-label manufacturing that can secure long-term B2B customers and higher-margin, repeat revenue streams.
Negative Factors
Persistent Unprofitability
Sustained negative net margins (~-22%) indicate the company has not yet demonstrated sustainable earnings power. Continued losses erode equity, limit reinvestment capacity, and force reliance on external funding, making long-term operational independence and scale-up more challenging.
Read all positive and negative factors
Positive Factors
Negative Factors
Manufacturing Capabilities
Owning cGMP-compliant extraction and manufacturing facilities is a durable competitive asset: it supports regulatory approvals, consistent product quality, and enables contract/private-label manufacturing that can secure long-term B2B customers and higher-margin, repeat revenue streams.
Read all positive factors
Epsilon Healthcare Limited (EPN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$8.56M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)-0.14
Revenue Growth-1.25%
EPS Growth-188.33%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)<0.01
Shares Outstanding389,104,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)4.19
Price to Sales (P/S)1.33
P/FCF Ratio-3.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Epsilon Healthcare Limited Business Overview & Revenue Model
Company Description
Epsilon Healthcare Limited (EPN) is an innovative healthcare company focused on developing and commercializing a range of therapeutic products and services. Operating primarily in the biotechnology and pharmaceutical sectors, EPN specializes in ca...
How the Company Makes Money
null...
Epsilon Healthcare Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
24
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.39M | 5.60M | 6.65M | 7.11M | 5.50M |
| Gross Profit | 2.25M | 4.17M | 4.81M | -3.09M | 2.06M |
| EBITDA | -1.86M | -2.13M | -1.31M | -10.86M | -8.09M |
| Net Income | -2.05M | -3.25M | -1.09M | -13.29M | -8.91M |
Balance Sheet | |||||
| Total Assets | 17.87M | 22.26M | 14.41M | 20.50M | 30.55M |
| Cash, Cash Equivalents and Short-Term Investments | 242.86K | 1.57M | 343.01K | 861.99K | 2.34M |
| Total Debt | 14.16M | 7.88M | 3.45M | 3.20M | 4.33M |
| Total Liabilities | 14.88M | 11.57M | 6.87M | 11.23M | 10.98M |
| Stockholders Equity | 2.99M | 10.70M | 7.54M | 9.27M | 19.57M |
Cash Flow | |||||
| Free Cash Flow | -3.30M | -3.50M | -803.47K | -3.10M | -6.18M |
| Operating Cash Flow | -3.13M | -3.41M | -703.37K | -2.57M | -5.43M |
| Investing Cash Flow | 6.29M | -97.73K | -99.12K | -529.40K | -737.59K |
| Financing Cash Flow | -4.48M | 4.73M | 335.91K | 1.61M | 1.47M |
Epsilon Healthcare Limited Technical Analysis
Negative
0.02
Price Trends
0.03
Negative
0.03
Negative
0.03
Negative
Market Momentum
>-0.01
Negative
41.46
Neutral
16.67
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EPN, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.46 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EPN.
Epsilon Healthcare Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | AU$136.69M | 13.85 | 19.15% | 4.33% | 8.46% | -1.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$46.19M | -69.17 | -0.79% | ― | 17.82% | ― | |
45 Neutral | AU$17.68M | -4.15 | -29.05% | ― | 45.30% | -24.18% | |
43 Neutral | AU$19.73M | -2.87 | 4388.00% | ― | -47.30% | 82.53% | |
42 Neutral | AU$8.56M | -6.11 | 649.03% | ― | -1.25% | -188.33% |
* Healthcare Sector Average
AU:EPN
Epsilon Healthcare Limited
0.02
>-0.01
-8.33%
AU:VLS
Vita Life Sciences Limited
2.51
0.76
43.43%
AU:LGP
Little Green Pharma Ltd.
0.10
-0.02
-19.17%
AU:MVP
Medical Developments International Limited
0.41
-0.11
-21.15%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-22.73%
AU:IDT
IDT Australia Limited
0.04
-0.05
-53.26%
Epsilon Healthcare Limited Corporate Events
Epsilon Healthcare Publishes 2025 Annual Report
Mar 31, 2026
Epsilon Healthcare Limited has released its 2025 Annual Report, which includes the chairman’s note, CEO report, directors’ report, remuneration details, and full audited financial statements. The document also covers shareholder inform...
Epsilon Healthcare Files Corporate Governance Statement and Appendix 4G
Mar 31, 2026
Epsilon Healthcare Limited has lodged its corporate governance statement for the financial year ended 31 December 2025, making it available on its website in line with ASX Listing Rule 4.10.3. The statement, current and board-approved as at 31 Mar...
Epsilon Healthcare Swings to Stronger Profit on 68% Revenue Surge
Feb 27, 2026
Epsilon Healthcare Limited reported a 68% increase in revenue from ordinary activities to $9.39 million for the year ended 31 December 2025, reflecting strong top-line growth in its healthcare operations. The company did not declare any interim or...
Epsilon Healthcare Seeks ASX Quotation for 5 Million New Shares
Feb 11, 2026
Epsilon Healthcare Limited has applied for quotation on the ASX of 5,000,000 new ordinary fully paid shares under the ticker EPN, with an issue date of 10 February 2026. The additional securities, arising from the exercise or conversion of existin...
Epsilon Healthcare Seeks ASX Quotation for 5 Million New Shares
Feb 6, 2026
Epsilon Healthcare Limited has applied to the ASX for quotation of 5 million new fully paid ordinary shares, issued on 4 February 2026. The additional securities arise from the exercise or conversion of existing options or other convertible instru...
Epsilon Healthcare Secures Three-Year Manufacturing Deal with Puro to Drive UK and EU Expansion
Feb 5, 2026
Epsilon Healthcare’s Epsilon Pharma unit has signed a three-year commercial manufacturing agreement with Puro New Zealand, the country’s largest medicinal cannabis cultivator, to produce GMP-certified finished products for export initi...
Epsilon Pharma Wins Halal Australia Certification for CBD and THC Oils, Targeting New Export Markets
Feb 3, 2026
Epsilon Healthcare’s wholly owned subsidiary Epsilon Pharma has secured Halal Australia certification for its CBD and THC oil dosage forms, confirming that its Australian manufacturing operations meet stringent Halal requirements and comply ...
Epsilon Healthcare Posts Record Quarter as ASX Reinstatement Caps Turnaround
Jan 28, 2026
Epsilon Healthcare reported record quarterly customer receipts of $2.891 million for the December 2025 quarter, a 96% increase on the prior corresponding period, and full-year receipts of $9.175 million, up 71% year-on-year, highlighting a strong ...
Epsilon Healthcare Director Increases Shareholding Through On‑Market Purchase
Jan 12, 2026
Epsilon Healthcare Limited has disclosed a change in director Zoe Hutchings’ shareholding, reflecting her direct ownership of fully paid ordinary shares in the company. The filing indicates a routine on‑market purchase rather than any ...
Epsilon Healthcare Director Increases On-Market Shareholding
Jan 6, 2026
Epsilon Healthcare Limited has disclosed a change in director Zoe Hutchings’ shareholding, indicating an increase in her direct ownership of the company’s fully paid ordinary shares. The filing shows that Hutchings acquired 519,426 sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.